Jade Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
3.8%projected annual EPS growth
Analyst Coverage
8analysts covering
FY EPS (est.)
-$2.93next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Phase 1 JADE301 Trial Commencement | 30 Jun 2027 |
Monitoring Framework
Key Performance Indicators
JADE101 IgA Reduction Percentage Quarterly70.0Target: Sustained >70% IgA reduction at steady state
Cash Runway (Years) Quarterly2.0Target: Fund operations into the first half of 2028
Watch Items
- Phase 2 JUNIPER clinical trial of JADE101 in IgA Nephropathy (IgAN)Trigger: Interim clinical data readout in 2027Action: Evaluate efficacy (proteinuria reduction) and safety to support Phase 3 registrational trial initiation
- Phase 1 clinical trial of JADE201 in Rheumatoid Arthritis (RA)Trigger: Interim clinical data readout in 2027Action: Assess safety, half-life extension, and B-cell depletion efficacy to guide Phase 2 dose selection
Research as of 19 Jun 2026